Aptose Biosciences price target lowered to $2 from $7 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Aptose Biosciences (APTO) to $2 from $7 and keeps a Buy rating on the shares. The firm expects share count and warrant increases to provide funding to advance tuspetinib further in the clinic. It also pushed out projected launch years of tuspetinib starting with 2027 to 2029.